6th Annual Project & Portfolio Management in the Pharmaceutical Industry

Jacob Fleming Conferences28 - 29 September 2010, Milan, Italy.
After 5 successful annuals and the industry feedback, Jacob Fleming Conferences is bringing a well-balanced program full of real life case studies on major achievements in Project & Portfolio Management Approaches established across leading Pharma companies.

Testimonials
"Good balance of speakers, great learning experience and excellent chairman!"
Director Research Project Management, MedImmune, UK

"Very high-quality & influential speakers."
Portfolio Director, AstraZeneca, UK

"Very practical, inspiring and high-level agenda. Very good conclusions from the chairman."
Senior Portfolio Manager, GlaxoSmithKline, Belgium

Expert Advisors
Head of Discovery Research, Roche, Switzerland
Vice President Portfolio Management, Strategic Planning, Bayer Schering Pharma, Germany
Vice President Project Management R&D, Amgen, USA
Scientific Vice President, Novo Nordisk, Denmark
Head R&D Portfolio Management, UCB, UK
Executive Vice President & Chief Scientific Officer, Ipsen, France
Executive Vice President Research & Development, Nycomed, Germany

Key speakers
Vice President Special Operations, Worldwide Research Centers of Emphasis, Pfizer, UK
Global Head Portfolio Management & Reporting, Sanofi Aventis, France
Head Global Project Management, Abbott, Germany
Global Head of Portfolio Management & Interfaces Discovery Research and Oncology, MerckSerono, Switzerland
Head Portfolio Management, Bayer Schering Pharma, Germany
Vice President Research, Lundbeck, Denmark
Senior Project Leader Cancer Immunotherapeutics, GSK Biologicals, Belgium

Key topics

  • Explore the ways how leading Pharma companies develop their portfolios to add value to key stakeholders
  • Trends in portfolio offerings – more for physicians, payers or patients?
  • The impact of current payer-driven environment and cost-containment initiatives on managing R&D projects
  • Achieving a balanced, rich & varied portfolio in a competitive and limited resources environment
  • Innovative approaches to managing Discovery Projects
  • Project Management in Late stage Development Projects
  • Prioritization and decision analysis tools –decision making on innovation
  • Balancing the risks in Project & Portfolio Management - Risk Management in PPM
  • Enhancing the innovation & strong portfolios through R&D collaborations and M&A – the role of alliance management & business development

Who should attend
Vice Presidents, Heads, Directors, Senior Managers and Managers of: Portfolio Management, Project Management, Pharmaceutical Development, R&D, Strategic Planning & Decision, Strategy & Portfolio Analysis, Portfolio Selection, Decision Analysis.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/6thPPM?partner=worldpharmanewsPPM

About Jacob Fleming Group
Jacob Fleming Conferences are carefully designed to provide key strategic business information and the best networking opportunities for the participants. Our business to business conferences are highly interactive events with a limited number of delegates from specialized industry sectors. For each conference Jacob Fleming brings together selected senior level executives who become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...

Soy lecithin NSAID combo drug protects against can…

When scientists at The University of Texas Health Science Center at Houston (UTHealth) applied a chemical found in soybeans to a non-steroidal anti-inflammatory drug (NSA...